横田 治重 よこた はるしげ 先生

来歴等

略歴

1982年 東京大学医学部医学科 卒業
1982年 東京大学医学部附属病院 産婦人科医員（研修医）
1983年 茨城県立中央病院 産婦人科医員
1984年 恩賜財団母子愛育会愛育病院 産婦人科医員
1985年 東京大学医学部産科婦人科学教室 文部教官助手
1987年 藤枝市立志太総合病院 産婦人科医員
1989年 国立がんセンター中央病院産婦人科 厚生技官助手
1990年 東京大学医学部産科婦人科学教室 文部教官助手
1995年 都立駒込病院 産婦人科医員
1995年 日立製作所日立総合病院 産婦人科主任医長
2003年 横田医院
2004年 埼玉県立がんセンター 婦人科科長兼部長
2014年 埼玉県立がんセンター 副病院長・地域連携・相談支援センター長
2020年 埼玉県立がんセンター 病院長

論文

• Trebananib orplacebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.Lancet Oncol. 2019 Jun;20(6):862-876.

  Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3 / ENGOT-ov2 / GOG-3001 investigators.

• Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial(JGOG1067). Gynecol Oncol. 2018 Jun;149(3):513-519.

  Matoda M, Takeshima N, Michimae H, Iwata T, Yokota H, Torii Y, Yamamoto Y, Takehara K, Nishio S, Takano H, Mizuno M, Takahashi Y, Takei Y, Hasegawa T, Mikami M, Enomoto T, Aoki D, Sugiyama T.

• Application of deep learning to the classification of images from colposcopy. Oncol Lett. 2018 Mar;15(3):3518-3523.

  Sato M, Horie K, Hara A, Miyamoto Y, Kurihara K, Tomio K, Yokota H.

• Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer.Oncotarget. 2017 Nov15;8(63):106866-106875.

  Matsuo K, Shimada M, Yokota H, Satoh T, Katabuchi H, Kodama S, Sasaki H, Matsumura N, Mikami M, Sugiyama T.

• Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.Eur J Cancer. 2016 Sep;64:22-31.

  Onda T, Satoh T, Saito T, Kasamatsu T, Nakanishi T, Nakamura K, Wakabayashi M, Takehara K, Saito M, Ushijima K, Kobayashi H, Kawana K, Yokota H, Takano M, Takeshima N, Watanabe Y, Yaegashi N, Konishi I, Kamura T, Yoshikawa H; Japan Clinical Oncology Group.

• Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients. Int J Clin Oncol. 2016 Apr;21(2):359-366.

  Tsuruga T, Fujimoto A, Kawana K, Mori M, Hasumi Y, Kino N, Tomio K, Miura S, Tanikawa M, Sone K, Miyamoto Y, Ikeda Y, Kojima S, Adachi K, Nagasaka K, Matsumoto Y, Arimoto T, Oda K, Nakagawa S, Horie K, Yasugi T, Yokota H, Osuga Y, Fujii T.

• Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A). Gynecol Oncol. 2015 Apr;137(1):34-9.

  Kato T, Takashima A, Kasamatsu T, Nakamura K, Mizusawa J, Nakanishi T, Takeshima N, Kamiura S, Onda T, Sumi T, Takano M, Nakai H, Saito T, Fujiwara K, Yokoyama M, Itamochi H, Takehara K, Yokota H, Mizunoe T, Takeda S, Sonoda K, Shiozawa T, Kawabata T, Honma S, Fukuda H, Yaegashi N, Yoshikawa H, Konishi I, Kamura T; Gynecologic Oncology Study Group of the Japan Clinical Oncology Group.

• Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour. Eur J Cancer. 2015 Feb;51(3):340-51

  Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y, Kikkawa F, Takeshima N, Hatae M, Yokota H, Saito T, Yaegashi N, Kobayashi H, Baba T, Kodama S, Saito T, Sakuragi N, Sumi T, Kamura T, Yoshikawa H.

• Gynecologic　Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-101.

  Fujiwara H, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K.

• Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study. Ann Oncol. 2014 May;25(5):1011-7.

  Sugiyama T, Fujiwara K, Ohashi Y, Yokota H, Hatae M, Ohno T, Nagai Y, Mitsuhashi N, Ochiai K, Noda K.

• Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Br J Cancer. 2013 Oct 1;109(7):1760-5.

  Takano M, Ochi H, Takei Y, Miyamoto M, Hasumi Y, Kaneta Y, Nakamura K, Kurosaki A, Satoh T, Fujiwara H, Nagao S, Furuya K, Yokota H, Ito K, Minegishi T, Yoshikawa H, Fujiwara K, Suzuki M.

• Phase III randomized controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stagesIB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG0102). Br J Cancer. 2013 May 28;108(10):1957-63.

  Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T, Yasugi T, Yaegashi N, Yokota H, Kodama S, Mizunoe T, Hiura M, Kasamatsu T, Shibata T, Kamura T; Japan Clinical Oncology Group.

• UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study. Eur J Gynaecol Oncol. 2013;34(2):120-3.

  Takano M, Goto T, Hirata J, Furuya K, Horie K, Takahashi M, Yokota H, Kino N, Kudoh K, Kikuchi Y.

• Clinicopathological prognostic factors and the role of cytoreduction in surgical stage IVb endometrial cancer: a retrospective multi-institutional analysis of 248 patients in Japan. Gynecol Oncol. 2012Nov;127(2):338-44.

  Eto T, Saito T, Kasamatsu T, Nakanishi T, Yokota H, Satoh T, Nogawa T, Yoshikawa H, Kamura T, Konishi I.

• [Treatment for adenocarcinoma and adenosquamous carcinoma of the uterine cervix]. Nihon Rinsho. 2012 Jun;70 Suppl 4:265-8.

  Yokota H.

• Is a low dose of concomitant chemotherapy with extended-field radiotherapy acceptable as an efficient treatment for cervical cancer patients with metastases to the para-aortic lymph nodes? Int J Gynecol Cancer. 2011Nov;21(8):1465-71.

  Kazumoto T, Kato S, Yokota H, Hasumi Y, Kino N, Horie K, Yoshida D, MizukamiT, Saito Y.

• Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol. 2010 Apr 1;28(10):1727-32.

  Satoh T, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, Yamaguchi S, Ochiai K, Takano M, Yokota H, Kawakami Y, Nishimura S, Ogishima D, Nakagawa S, Kobayashi H, Shiozawa T, Nakanishi T, Kamura T, Konishi I, Yoshikawa H.

• Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology. 2009;76(5):315-21.

  Takano M, Kato M, Yoshikawa T, Sasaki N, Hirata J, Furuya K, Takahashi M, Yokota H, Kino N, Horie K, Goto T, Fujiwara K, Ishii K, Kikuchi Y, Kita T.